We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Fulcrum Therapeutics Inc
12 own
7 watching
Current Price
$3.42
$-0.12
(-3.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
383.68M
52-Week High
13.70000
52-Week Low
2.86500
Average Volume
0.46M
Dividend Yield
--
P/E Ratio
--
Market Capitalization383.68M52-Week High13.7000052-Week Low2.86500Average Volume0.46MDividend Yield--P/E Ratio--What does the Fulcrum Therapeutics Inc do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Fulcrum Therapeutics Inc make?
News & Events about Fulcrum Therapeutics Inc.
Zolmax
1 year ago
Fulcrum Therapeutics (NASDAQ:FULC Free Report) and Lyell Immunopharma (NASDAQ:LYEL Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ...
Globe Newswire
1 year ago
BENSALEM, Pa., June 27, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ...
Globe Newswire
1 year ago
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fulcrum investors who were adversely...
Globe Newswire
1 year ago
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey...
Globe Newswire
1 year ago
NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edgio, Inc. (NASDAQ: EGIO), Fulcrum Therapeutics, Inc. (NASDAQ: FULC), adidas AG (OTC: ...
Frequently Asked Questions
Frequently Asked Questions
What is Fulcrum Therapeutics Inc share price today?
Can Indians buy Fulcrum Therapeutics Inc shares?
How can I buy Fulcrum Therapeutics Inc shares from India?
Can Fractional shares of Fulcrum Therapeutics Inc be purchased?
What are the documents required to start investing in Fulcrum Therapeutics Inc stocks?
What is today’s traded volume of Fulcrum Therapeutics Inc?
What is today’s market capitalisation of Fulcrum Therapeutics Inc?
What is the 52-Week High and Low Range of Fulcrum Therapeutics Inc?
What percentage is Fulcrum Therapeutics Inc down from its 52-Week High?
What percentage is Fulcrum Therapeutics Inc up from its 52-Week Low?
Current Price
$3.42
$-0.12
(-3.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.